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Abstract
Background: Hepatic injury has been reported following duloxetine use. This study further examines the hepatic
safety of duloxetine in a large US health insurance database.
Methods: In this propensity score-matched cohort analysis in a US commercially insured population (01 August 2004
to 31 December 2010), we compared individuals with depression and without liver disease who initiated duloxetine to
comparators (venlafaxine or selective serotonin reuptake inhibitors [SSRIs], and individuals with pharmacologically
untreated depression). We estimated incidence rates (IR) and 95 % confidence intervals (CI) for medical
record-confirmed hepatic-related death, liver failure, and other clinically significant hepatic injury.
Results: Among 30,844 duloxetine initiators, 21,000 were matched to venlafaxine initiators, 28,479 to SSRI initiators,
and 22,714 to untreated patients. There were no cases of hepatic-related death or liver failure. IRs of other clinically
significant hepatic injury without documented alternate etiologies were higher but not statistically significant among
duloxetine initiators compared to initiators of venlafaxine (0.7/1000 person-years [PY] [95 % CI: 0.2 − 1.5] vs. 0.0/1000
PY [95 % CI: 0.0 − 0.3]) and SSRIs (0.4/1000 PY [95 % CI: 0.1 − 1.0] vs. 0.0/1000 PY [95 % CI: 0.0 − 0.3]). IRs were similar
among duloxetine and untreated patients (0.5/1000 PY [95 % CI: 0.1 − 1.3] vs. 0.5/1000 PY [95 % CI: 0.1 − 1.5]). When
hepatic outcomes were considered irrespective of alternate etiologies, similar results were observed.
Conclusions: Our findings, while not statistically significant, may suggest a higher incidence of hepatic injury
other than hepatic-related death or liver failure among duloxetine initiators compared to venlafaxine and possibly
SSRIs, but not untreated patients. These differences remain consistent with chance, and an elevated risk cannot
be ruled in or out.
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Background
Duloxetine (Cymbalta; Eli Lilly and Company, Indianapolis,
IN, USA) is a serotonin-norepinephrine reuptake inhibitor
(SNRI) approved in 2004, with indications for the
treatment of major depressive disorder, diabetic per-
ipheral neuropathic pain, fibromyalgia, generalized
anxiety disorder, stress urinary incontinence (in Euro-
pean Union), and chronic pain states associated with
chronic lower back pain and osteoarthritis (in some
geographies).
Drug-induced liver injury (DILI) is the most frequent
cause of acute liver failure in the United States (US) and
a frequent reason for withdrawal of a drug from the
market [1, 2]. Elevations of alanine aminotransferase to
three times the upper limit of normal were observed in
clinical trials in approximately 1 % of duloxetine-treated
depressed recipients [3]. Hepatic injury with a hepatocel-
lular, cholestatic, or mixed pattern has also been re-
ported rarely in association with duloxetine during the
post-marketing period [4, 5].
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While DILI has been reported with several antidepres-
sant agents [6, 7], information regarding the risk for liver
injury in patients treated with duloxetine and compari-
sons with other antidepressants in routine clinical
practice remains limited. A recent study by Xue et al. re-
vealed that for hepatic injury of lesser severity such as
elevated aminotransferases, duloxetine was associated
with a higher incidence relative to the venlafaxine and
non-depressed cohorts, but not relative to the selective
serotonin reuptake inhibitor (SSRI) cohort [8]. However,
for serious liver injury such as hepatic failure and
hepatic-related death, the duloxetine and other anti-
depressant cohorts did not differ significantly and the
overall hepatic safety profiles of duloxetine and SSRIs
were similar, albeit with modest statistical power. The
study by Xue et al., conducted within data from a com-
mercial health plan, was restricted to the first 2 years
following the launch of duloxetine in the US and in-
cluded patients with and without baseline hepatic risks
and active liver disease, complicating determinations of
the association between duloxetine and liver injury. We
performed a follow-up retrospective cohort study within
the same database, with expanded accrual to include
data from the first 6 years following the launch of dulox-
etine. To minimize the capture of non-drug-related liver
injury and provide a specific focus on clinically signifi-
cant potential drug-related liver injury, this study was re-
stricted to subjects without pre-existing liver conditions.
The objective of this study was to estimate the absolute
and relative incidence of clinically significant hepatic
events among patients with depression and without pre-
existing liver disease who initiated duloxetine relative to
each of the following propensity score-matched compari-
son cohorts: patients with depression who initiated venla-
faxine, patients with depression who initiated SSRIs, and
patients with a diagnosis of depression who did not re-
ceive treatment.
Methods
Data source and study population
Data included in this retrospective cohort study came
from the Optum Research Database (ORD), an elec-
tronic health care database of a large US health plan in-
cluding demographics, pharmacy use, and medical and
facility claims, which provide dates on services, proce-
dures, and their accompanying diagnoses. The population
is geographically diverse and comprises approximately
3–4 % of the US population.
We included commercially insured health plan mem-
bers 18 years of age or older, with complete medical
coverage and pharmacy benefits, who:
 initiated a study antidepressant (duloxetine,
venlafaxine, or an SSRI) between 01 August 2004
and 31 September 2010 (first dispensing following
12 months of continuous enrollment without similar
dispensing) or who had an inpatient or outpatient
physician diagnosis of depression (International
Classification of Diseases, Ninth Revision [ICD-9],
codes 311.x, 296.x, 309.x, or 300.x) without
dispensings for an antidepressant medication
 had at least 12 months prior continuous enrollment
criteria (baseline period);
 had a claim for diagnosis of depression during the
12-month baseline period.
We excluded members if they had a diagnosis for a
hepatic condition during the baseline period (Table 1),
or if they were located in the Louisiana and Mississippi
regions with cohort entry date prior to 01 September
2006, as the availability of medical records during this
period was likely to be affected by disruptions following
Hurricane Katrina. Subjects who qualified as initiators of
more than one study drug entered the cohort of the
earliest initiated study drug. Cohort entry occurred on
the date of dispensing of the cohort-defining antidepres-
sant (treated cohorts) or an office visit associated with a
claim with a depression diagnosis (pharmacologically
untreated cohort).
Approval of the study protocol and waiver of patient
authorization were obtained from the New England
Institutional Review Board and affiliated Privacy Board.
Exposure assessment
We defined exposure according to subjects’ initial cohort
assignment (initiator of duloxetine, venlafaxine, or an
SSRI, or patient with pharmacologically untreated de-
pression). This “as-matched” exposure classification is
analogous to “intent-to-treat” analyses used in random-
ized trials.
Outcome assessment
The primary outcomes were cases of clinically significant
hepatic injury, defined as 3 distinct categories informed
by criteria in Chalasani et al. [9] and de Abajo [10] and
2 composite categories (Table 2):
 hepatic-related death
 liver failure
 other clinically significant hepatic injury
 hepatic-related death or liver failure combined
 all clinically significant hepatic outcomes combined.
The secondary outcome was non-serious asymptom-
atic hepatic enzyme elevations.
Potential cases were identified on the basis of ICD-9
diagnosis or procedure codes. An independent clinician
blinded to drug exposure reviewed claims for each
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potential case and selected an appropriate provider to
obtain medical records for those with claims consistent
with the occurrence of a study outcome. Two independ-
ent academic hepatologists reviewed the medical records
of each potential case and adjudicated case status attrib-
uting cases identified from any administrative code to
the most severe category for which the event qualified.
They identified the most severe hepatic event confirmed
for the episode of care, determined whether an alternate
etiology for a confirmed hepatic event was explicitly
identified based on their expert clinical opinion, and
identified the date of diagnosis based on the clinical data
in the medical record. Discrepancies between the 2 re-
viewers were resolved by consensus. Hepatic deaths were
confirmed through a combination of medical record re-
view and linkage to the National Death Index (NDI) [11]
through 31 December 2010. Deaths from hepatic condi-
tions were identified by ICD-10 codes indicating hepatic
disorders (B15-B19, K70-K77, B94.2, R17, R18) as a
listed cause of death in the NDI.
Covariate assessment and propensity score estimation
We ascertained a range of characteristics, including psy-
chological comorbidities, hepatic comorbidities and risk
factors, medications, and health care services, that were
specified a priori and ascertained based on the presence
of diagnoses, procedures, and pharmacy dispensings in
the health care claims during the 12-month baseline.
Additional baseline covariates were empirically identified
by listing the 100 most frequent drug classes dispensed
to the duloxetine initiator cohort during the baseline
period, along with the most frequent diagnoses (at the
3-digit ICD-9 level) and procedures (based on Current
Procedural Terminology (CPT) codes). These baseline
characteristics were included in the propensity score
analysis.
Duloxetine initiators were matched on a 1:1 ratio to
each of the other 3 comparator cohorts (venlafaxine, SSRI,
pharmacologically untreated) on the basis of estimated
propensity scores, independently within calendar blocks of
cohort accrual with the purpose of balancing the cohorts
with respect to baseline characteristics [12–16]. Propen-
sity scores were estimated using logistic regression models
of exposure (duloxetine or comparator) on covariates,
with a forced inclusion of variables identified a priori, and
stepwise selection of remaining variables.
Follow-up
We followed subjects from the day following cohort
entry to the earliest of: discontinuation of study drug (or
for the pharmacologically untreated cohort, initiation of
a study drug); disenrollment from the health plan; occur-
rence of a study outcome event (followed separately for
each outcome category); or 31 December 2010. Patients
for whom the first claims-identified event was not con-
firmed via medical record review or for whom medical
charts could not be obtained for review were censored
on the date of the claims-identified event.
Table 1 Hepatic conditions exclusion criteria, identified on the










Acute or sub-acute necrosis of liver











Unspecified or cryptogenic hepatitis
Nonalcoholic hepatitis
Biliary tract obstruction, stricture, stones
Primary or metastatic neoplasia of the liver and hepatic ducts












Liver helminth, fluke, parasite
Budd-Chiari Syndrome
Abdominal trauma
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“Time to treatment discontinuation” was defined pri-
marily as the time from cohort entry through 15 days fol-
lowing discontinuation of treatment based on dates of
dispensing and days supply (primary definition). To assess
the impact of varying the length of the observation win-
dow on estimated effects, two additional definitions were
applied in secondary analyses: (1) time from cohort entry
through 30 days following discontinuation of treatment;
and (2) time restricted to the 1st 90 days following cohort
entry. For patients in the untreated depression cohort,
each patient was assigned a proxy “treatment discontinu-
ation” date corresponding to the date of treatment discon-
tinuation of their matched duloxetine comparator.
Statistical analysis
Main analyses
Baseline characteristics were tabulated for the cohorts
prior to matching and within the matched cohorts, using
frequencies and proportions for categorical variables, and
means and standard deviations for continuous variables.
To assess whether potential imbalances remained after
propensity score matching, absolute standardized differ-
ences were calculated for covariates included in the pro-
pensity score model [17, 18]; variables with an absolute
standardized difference >0.1 after propensity score match-
ing were identified as potential confounders for inclusion
in multivariable outcome models.
Incidence rates of hepatic injury were calculated as the
number of confirmed cases divided by the relevant
person-time. We also estimated 95 % confidence inter-
vals (CIs) of the IRs for the duloxetine initiator and
comparator cohorts. Incidence rate ratios (IRR) and as-
sociated 95 % CIs comparing the rate of clinically signifi-
cant hepatic injury among duloxetine initiators with
each of the 3 comparator cohorts were estimated using
exact methods.
We limited primary outcomes to cases of hepatic in-
jury without explicit identification of an alternative eti-
ology, and assessed the impact of excluding cases on the
basis of alternate etiology through comparison to a
Table 2 Hepatic outcome definitions
Hepatic outcome Definition
Hepatic-related death Fatality where the underlying or any of the contributory causes of death in
the death certificate was a hepatic event based on linkage to the National
Death Index (NDI), or in the absence of a death certificate, where there is evidence
of an underlying hepatic event on the basis of health insurance claims in relation
to the death
Liver failure (non-fatal), in the absence of explicit
identification of an alternative etiology
Liver failure, not resulting in death, defined by the following conditions
● Hepatic failure
● Fulminant hepatitis (non-infectious)
● Hepatic encephalopathy
● Hepatic coma
● Liver transplant or renal and liver transplant
● When explicitly associated with acute liver disease:
● Acquired coagulation factor V deficiency due to liver disease (factor V level <30 %)
● Acquired hypoprothrombinemia
● International normalized ratio (INR) >1.5, prothrombin time >16 s
Other clinically significant hepatic injury, in the absence
of explicit identification of an alternative etiology
Hepatic injury, defined by any of the following:
● ALT > 500 IU/ml or ≥10x ULN, with any of the following: incident toxic hepatitis;
incident acute hepatitis; incident hepatic necrosis; incident toxic liver disease; or
incident toxic hepatitis
● ALT > 250 IU/mL or > 5x ULN with any of the following: nausea/vomiting; abdominal
pain; weakness; or fatigue
● ALT > 3x ULN with any of the following: jaundice/icterus when alkaline phosphatase
<2x ULN; ascites; or a combination of total bilirubin >2x ULN (Hy’s rule) and alkaline
phosphatase <2x ULN
Non-serious hepatic enzyme elevation, in the absence
of explicit identification of an alternative etiology
Presence of the combination of all the following, provided the patient is asymptomatic:
● 5x ULN < ALT <10x ULN
● T bilirubin <2x ULN
● Any ICD-9 hepatic code, validated by medical record review, when no symptoms
associated with it and in absence of any codes for hepatic failure or serious hepatic
injury (hepatic coma, jaundice, ascites, etc.)
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secondary analysis in which all confirmed hepatic out-
comes were included [19].
Sensitivity analyses
Insurance claims might incompletely capture covariates
or study exclusions, especially those related to hepatic
injury (e.g., abnormal liver function test results). We
therefore assessed the completeness of covariate and ex-
clusion capture through additional sampled medical rec-
ord review. Characteristics relating to depression and
hepatic risk factors, such as past hepatitis, alcohol use,
and other data (e.g., liver function test results) were
ascertained through review of medical records from
around the time of cohort entry for 1260 randomly
selected duloxetine initiators and propensity score-
matched comparators (315 from each cohort).
To assess the potential for bias introduced by differen-
tial loss to follow-up, patients who were censored during
follow-up were characterized according to their baseline
characteristics, by matched cohort.
All analyses were conducted using SAS version 9.2
(SAS Institute, Inc., Cary, NC).
Ethics approval
The New England Institutional Review Board approved
this study, and the Privacy Board approved a waiver of




From 01 August 2004 to 30 September 2010, 30,844 ini-
tiators of duloxetine, 29,243 initiators of venlafaxine,
166,236 initiators of SSRI, and 311,338 subjects with
pharmacologically untreated depression met eligibility
criteria prior to propensity score matching (Table 3).
Of the duloxetine initiators, the following numbers
were matched in a 1:1 ratio to each of the other groups:
21,000 (68.1 %) to venlafaxine initiators, 28,479 (92.3 %)
to SSRI initiators, and 22,714 (73.6 %) to patients with a
diagnosis of depression who did not receive an anti-
depressant. Conversely, 21,000 out of 29,243 (71.8 %)
venlafaxine initiators, 28,479 out of 166,236 (17.1 %)
SSRI initiators, and 22,714 out of 311,338 (7.3 %) pa-
tients in the untreated cohort were matched to duloxe-
tine initiators.
Descriptive baseline characteristics
Prior to propensity score matching, duloxetine initiators
were more likely to be older compared to the other 3
comparator cohorts, and were more likely to be female
compared to the SSRI and pharmacologically untreated
depression cohorts. Duloxetine initiators also had a
higher prevalence a wide range of a priori-defined char-
acteristics representing baseline neuropsychological co-
morbidities, hepatic risk factors, medication use, and
health services utilization.
Matching on propensity score resulted in matched
duloxetine initiator and comparator cohorts that were
well-balanced for most measured baseline characteristics
retained in the final propensity score models (Table 4).
Standardized difference scores did not exceed the
threshold of >0.1 for any of the variables included in the
propensity scores.
Identification and confirmation of hepatic events
There were 969 potential cases of clinically significant
hepatic injury for 962 individuals among the propensity
score-matched cohorts (nine hepatic-related deaths, 32
liver failure events, and 928 other clinically significant
hepatic injury events). Of these, 74 % (716) of charts (six
hepatic-related deaths, 25 liver failure events, and 685
other clinically significant hepatic injury events) repre-
senting 712 individuals were available for abstraction
and review by the clinical consultants.
Fifty-four of the 716 abstracted potential cases (repre-
senting 53 unique events) were confirmed as a clinically
significant hepatic injury or a non-serious asymptomatic
hepatic enzyme elevation. An alternate etiology was
identified for 35 of the 54 hepatic events; these included
cases adjudicated as having documentation of acetomi-
nophen toxicity, cholelithiasis with or without pancrea-
titis, liver injury following motor vehicle accident, sepsis,
hepatitis C virus, Epstein Barr virus, fatty liver disease,
alcohol-related injury, hypotension, other medications,
pancreatic cancer, and lymphoma. The remaining 18
events (zero hepatic-related death, zero liver failure, 12
other clinically significant hepatic injury, six non-serious
hepatic enzyme elevation) were adjudicated as possible
or definite drug-associated liver injury.
When observation was restricted to the primary
follow-up window (time to treatment discontinuation
plus 15 days), 41 unique confirmed events remained, of
which 11 were adjudicated as possible or definite drug-
associated liver injury (zero hepatic-related death, zero
liver failure, eight other clinically significant hepatic in-
jury, three non-serious enzyme elevation).
One case in the duloxetine cohort was initially con-
firmed by independent adjudicators as a hepatic injury
event without alternate etiology, but after completion of
the analyses, a further review of the health care claims
occurring within 45 days prior to adjudicated event date
for this case indicated the presence of diagnosis codes in
the claims data consistent with alternate etiologies of
acute viral infection and chronic liver disease, cirrhosis,
or fibrosis. We conducted an additional clinical review
of the medical record for this case. In the additional
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Table 3 Study eligibility and exclusions
Duloxetine Venlafaxine SSRI Untreated
N removed N eligible remaining N removed N eligible remaining N removed N eligible remaining N removed N eligible remaining
Member of commercial health insurance plan,
with medical coverage and pharmacy benefits,
and presence of qualifying eventa during the
accrual period
156,682 (100.0 %) 231,793 (100 %) 1,314,147 (100 %) 1,577,784 (100 %)
Baseline exclusions
Less than 18 years at index date 1396 155,286 (99.1 %) 2482 229,311 (98.9 %) 33,476 1,280,671 (97.5 %) 60,552 1,517,232 (96.2 %)
Less than 12 months prior continuous enrollment 79,819 75,467 (48.2 %) 136,147 93,164 (40.2 %) 780,943 499,728 (38.0 %) 791,027 726,205 (46.0 %)
Prior dispensing of study drug or drug class
in the baseline
0 75,467 (48.2 %) 23,753 69,411 (29.9 %) 134,294 365,434 (27.8 %) 334,496 391,709 (24.8 %)
Had no depression diagnosis in the baseline 27,596 47,871 (30.6 %) 24,844 44,567 (19.2 %) 153,173 212,261 (16.2 %) 0 391,709 (24.8 %)
Had hepatic injury/chronic hepatic condition
in the baseline
10,592 37,279 (23.8 %) 9173 35,394 (15.3 %) 39,354 172,907 (13.2 %) 76,815 314,894 (20.0 %)
Region affected by Hurricane Katrina 489 36,790 (23.5 %) 509 34,885 (15.1 %) 2020 170,887 (13.0 %) 3556 311,338 (19.7 %)
Cohort assignment based on earliest qualifying
index date (pre-propensity score matching)
30,844 (19.7 %) 29,243 (12.6 %) 166,236 (12.6 %) 311,338 (19.7 %)












Table 4 Baseline characteristics among duloxetine and comparator propensity score-matched cohorts, ORD, 01 August 2004–30
September 2010
Baseline Characteristic Duloxetine-Venlafaxine Duloxetine-SSRI Duloxetine-Untreated
Duloxetine Venlafaxine Duloxetine SSRIs Duloxetine Untreated
(N = 21,000) (N = 21,000) (N = 28,479) (N = 28,479) (N = 22,714) (N = 22,714)
N % N % N % N % N % N %
Age group (years)
18–25 1855 8.8 1807 8.6 2154 7.6 2057 7.2 1829 8.1 1812 8.0
26–30 1748 8.3 1758 8.4 2070 7.3 1992 7.0 1746 7.7 1764 7.8
31–35 2473 11.8 2487 11.8 3101 10.9 3128 11.0 2493 11.0 2501 11.0
36–40 3067 14.6 2979 14.2 4034 14.2 4008 14.1 3160 13.9 3108 13.7
41–50 6152 29.3 6218 29.6 8667 30.4 8733 30.7 6725 29.6 6703 29.5
51–60 4371 20.8 4419 21.0 6390 22.4 6436 22.6 5041 22.2 5030 22.1
61–70 1176 5.6 1175 5.6 1817 6.4 1871 6.6 1506 6.6 1582 7.0
≥ 71 158 0.8 157 0.7 246 0.9 254 0.9 214 0.9 214 0.9
Female 15,074 71.8 15,092 71.9 20,570 72.2 20,405 71.6 15,974 70.3 16,020 70.5
Number of unique ICD-9 codes
0–4 1924 9.2 1948 9.3 2291 8.0 2169 7.6 2019 8.9 1894 8.3
5–8 4228 20.1 4208 20.0 5002 17.6 5006 17.6 4270 18.8 4145 18.2
9–12 4603 21.9 4657 22.2 5893 20.7 6039 21.2 4874 21.5 4866 21.4
13–16 3706 17.6 3704 17.6 5059 17.8 5086 17.9 4071 17.9 4092 18.0
17+ 6539 31.1 6483 30.9 10,234 35.9 10,179 35.7 7480 32.9 7717 34.0
Number of different drugs dispensed
0–3 2525 12.0 2410 11.5 2656 9.3 2253 7.9 2640 11.6 2482 10.9
4–7 6365 30.3 6427 30.6 7553 26.5 7654 26.9 6890 30.3 6873 30.3
8+ 12,110 57.7 12,163 57.9 18,270 64.2 18,572 65.2 13,184 58.0 13,359 58.8
Total costs (mean std) 7944.9 14,910.5 7685.7 14,071.0 9354.0 16,773.2 9113.6 18,729.4 8295.0 15,748.1 8201.4 15,713.5
Psychotic disorders 7746 36.9 7685 36.6 11,187 39.3 11,029 38.7 7345 32.3 7349 32.4
Fibromyalgia 1936 9.2 1858 8.8 3760 13.2 3625 12.7 2610 11.5 2620 11.5
Back pain 2974 14.2 2863 13.6 4916 17.3 4921 17.3 3658 16.1 3764 16.6
Bilirubin test 971 4.6 972 4.6 1364 4.8 1350 4.7 1042 4.6 1031 4.5
ALT/AST/ALP test 788 3.8 790 3.8 1205 4.2 1208 4.2 924 4.1 952 4.2
NSAID use (excluding diclofenac) 5643 26.9 5730 27.3 8573 30.1 8591 30.2 6534 28.8 6776 29.8
Use of other medications
Diclofenac 736 3.5 710 3.4 1206 4.2 1203 4.2 900 4.0 920 4.1
Valproic acid 408 1.9 439 2.1 653 2.3 673 2.4 451 2.0 471 2.1
Nitrofurantoin 796 3.8 773 3.7 1146 4.0 1121 3.9 875 3.9 962 4.2
Fluconazole 1684 8.0 1701 8.1 2428 8.5 2417 8.5 1872 8.2 1974 8.7
Statins 3008 14.3 3002 14.3 4518 15.9 4666 16.4 3584 15.8 3609 15.9
Anticonvulsants 5403 25.7 5406 25.7 8817 31.0 8745 30.7 5799 25.5 5774 25.4
Anxiolytics or sedative hypnotics 10,192 48.5 10,072 48.0 14,698 51.6 14,701 51.6 10,673 47.0 10,724 47.2
Antihistamines 4364 20.8 4315 20.5 6230 21.9 6183 21.7 4699 20.7 4920 21.7
Antipsychotics 1689 8.0 1710 8.1 2549 9.0 2510 8.8 1455 6.4 1773 7.8
Narcotic analgesics 9533 45.4 9452 45.0 14,366 50.4 14,339 50.3 10,923 48.1 11,090 48.8
ORD Optum Research Database, SSRI selective serotonin reuptake inhibitor, ALT alanine aminotransferase, AST aspartate aminotransferase, ALP alkaline
phosphatase, NSAID nonsteroidal anti-inflammatory drug, ICD-9 International Classification of Diseases, 9th Edition, std standard deviation
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review, the reviewers re-confirmed the case was a hep-
atic injury event, but contrary to their initial assessment,
adjudicated the case as a confirmed hepatic injury event
with alternate etiology. As this posthoc review of the sin-
gle case occurred several months following the initial
main review and was undertaken outside of the protocol,
all analyses presented are based on data from the
protocol-specified clinical review only.
Incidence of liver injury
Considering cases of hepatic injury without an alternate
etiology, zero cases of hepatic-related death and zero
cases of liver failure were confirmed (Table 5). For the
outcome, other clinically significant hepatic injury, the
IR among duloxetine initiators was 0.7 per 1000 person-
years (95 % CI: 0.2, 1.5) among those matched to venla-
faxine compared to 0.0 per 1000 person-years (95 % CI:
0.0, 0.3) among venlafaxine initiators, and was 0.4 per
1000 person-years (95 % CI: 0.1, 1.0) among those
matched to SSRI compared to 0.0 per 1000 person-years
(95 % CI: 0.0, 0.3) among SSRI initiators. IRs were similar
among duloxetine initiators and the matched untreated
cohort (0.5 per 1000 person-years [95 % CI: 0.1, 1.3]
among duloxetine initiators vs. 0.5 per 1000 person-years
[95 % CI: 0.1, 1.5] among untreated comparators). For the
outcome, non-serious hepatic enzyme elevations, a total
of 3 events were confirmed among the study cohorts
(1 duloxetine, 2 SSRI), corresponding to an IR of 0.1 per
1000 person-years (95 % CI: 0.0, 0.5) among duloxetine
initiators and an IR of 0.2 per 1000 person-years (95 % CI:
0.0, 0.7) among SSRI initiators. Varying the length of the
exposure (through restriction to the 1st 90 days following
cohort entry, or expansion to include time on therapy
through 30 days following treatment discontinuation) pro-
duced substantively similar results as the primary analysis
(data not shown).
When all confirmed hepatic outcomes were consid-
ered irrespective of alternate etiologies, similar results
were observed (Table 6). Duloxetine initiators had an IR
suggestive of elevated risk for all clinically significant
hepatic injuries combined when compared with initia-
tors of venlafaxine (IRR: 3.2; exact 95 % CI: 0.9, 13.7).
Smaller elevations were observed comparing duloxetine
initiators to initiators of SSRIs (IRR: 1.3; exact 95 % CI:
0.5, 3.3), while IRs observed among duloxetine initiators
and the untreated cohort were similar (IRR: 1.0; exact
95 % CI: 0.4, 2.9).
Sensitivity analyses
Medical record validation of baseline comparability
From the 315 individuals randomly selected from each
of the duloxetine and comparator cohorts, a total of 213
charts (68 %), 212 charts (67 %), 223 charts (71 %), and
212 charts (67 %) were abstracted for the duloxetine,
venlafaxine, SSRI, and untreated cohorts, respectively.
Compared to venlafaxine initiators, alcohol use/abuse
was less frequently documented among the matched
duloxetine initiators (5.1 % vs. 8.5 %), while current
smoking was more frequently documented among
duloxetine initiators (21.5 % vs. 16.5 %). Approximately
3.8 % of duloxetine initiators and 4.7 % of venlafaxine
initiators had a record of abnormal liver enzymes, while
1.3 % of duloxetine initiators and 0.5 % of venlafaxine
initiators had chronic liver disease documented in the
medical records.
Compared to SSRI initiators with abstracted medical
records, matched duloxetine initiators had a higher
baseline prevalence of current smoking (20.7 % vs.
11.2 %), obesity (21.2 % vs. 18.8 %), and alcohol use/
abuse (6.4 % vs. 3.1 %). SSRI and duloxetine initiators
had a similar prevalence of documented abnormal liver
enzymes (3.5 % vs. 3.6 %) and chronic liver disease (1.5 %
vs. 0.9 %).
Compared to untreated individuals with abstracted
medical records, duloxetine initiators were slightly more
likely to have documented alcohol use/abuse (6.7 % vs.
3.8 %) and a record of abnormal liver enzymes (4.7 %
vs. 2.8 %).
Similar patterns of attrition were observed across the
study cohorts, with censoring of between 54-59 % of
subjects in the duloxetine, venlafaxine, and SSRI cohorts
within the first 8 weeks following initiation of the study
drugs and 47 % of subjects in the untreated cohort
within the same time frame. Comparison of these pa-
tients to the overall duloxetine and matched comparator
cohorts suggests that patients who dropped out at any
time during study follow-up had similar baseline charac-
teristics as the overall matched cohorts (unpublished).
Discussion
In our study, no confirmed cases of hepatic-related
death or hepatic failure were identified. We found that
duloxetine initiators had a statistically non-significant
higher incidence rate of other clinically significant hep-
atic injuries compared to initiators of venlafaxine, and a
more modest elevation compared to initiators of SSRIs.
These differences are consistent with a hypothesis of
similar outcome among initiators of duloxetine and the
treated comparator study drugs, and an elevated risk
cannot be ruled in or out. No differences in the inci-
dence of clinically significant hepatic outcomes were ob-
served in the duloxetine and untreated comparator
cohorts.
Potential hepatic injuries, such as elevated hepatic
enzyme levels have been reported for duloxetine in pre-
marketing clinical trials and in the post-marketing
period [6], but these reports have, in some cases, been
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associated with excessive alcohol use or pre-existing liver
disease. The IRs of clinically significant hepatic events
observed in our study are comparable or slightly lower
than those observed in the earlier safety study of
duloxetine conducted in the Optum Research Database
[8]. The earlier assessment using the Optum Research
Database found higher incidence rates of hepatic injury
of lesser severity among duloxetine users relative to
Table 5 IRs, IRRs, and 95 % confidence intervals of hepatic events without identified alternate etiology, follow-up through 15 days
following treatment discontinuation, matched duloxetine and comparator cohorts, ORD, 01 August 2004 to 31 December 2010
Outcome Cohort Person-Years No. Cases IR 95 CI % IRR 95 % CI
Hepatic-related death Duloxetine 7633.5 0 0.0 (0.0, 0.4) NA NA
Venlafaxine 8838.7 0 0.0 (0.0, 0.3)
Duloxetine 10,411.9 0 0.0 (0.0, 0.3) NA NA
SSRI 9835.6 0 0.0 (0.0, 0.3)
Duloxetine 8116.7 0 0.0 (0.0, 0.4) NA NA
Untreated 5966.1 0 0.0 (0.0, 0.5)
Hepatic failure Duloxetine 7631.7 0 0.0 (0.0, 0.4) NA NA
Venlafaxine 8836.6 0 0.0 (0.0, 0.3)
Duloxetine 10,410.6 0 0.0 (0.0, 0.3) NA NA
SSRI 9833.9 0 0.0 (0.0, 0.3)
Duloxetine 8116.2 0 0.0 (0.0, 0.4) NA NA
Untreated 5965.8 0 0.0 (0.0, 0.5)
Other clinically significant hepatic injurya Duloxetine 7548.5 5 0.7 (0.2, 1.5) undef. (1.1, inf.)
Venlafaxine 8745.2 0 0.0 (0.0, 0.3)
Duloxetine 10,300.9 4 0.4 (0.1, 1.0) undef. (0.6, inf.)
SSRI 9753.2 0 0.0 (0.0, 0.3)
Duloxetine 8035.8 4 0.5 (0.1, 1.3) 1.0 (0.2, 6.7)
Untreated 5931.9 3 0.5 (0.1, 1.5)
Hepatic-related death and liver failure combined Duloxetine 7631.7 0 0.0 (0.0, 0.4) NA NA
Venlafaxine 8836.6 0 0.0 (0.0, 0.3)
Duloxetine 10,410.6 0 0.0 (0.0, 0.3) NA NA
SSRI 9833.8 0 0.0 (0.0, 0.3)
Duloxetine 8116.2 0 0.0 (0.0,0.4) NA NA
Untreated 5965.6 0 0.0 (0.0, 0.5)
All clinically significant hepatic categories combined Duloxetine 7548.5 5 0.7 (0.2, 1.5) undef. (1.1, inf.)
Venlafaxine 8745.2 0 0.0 (0.0, 0.3)
Duloxetine 10,300.9 4 0.4 (0.1, 1.0) undef. (0.6, inf.)
SSRI 9753.2 0 0.0 (0.0, 0.3)
Duloxetine 8035.8 4 0.5 (0.1, 1.3) 1.0 (0.2, 6.7)
Untreated 5931.9 3 0.5 (0.1, 1.5)
Non-serious hepatic enzyme elevation Duloxetine 7548.5 1 0.1 (0.0, 0.7) undef. (0.0, inf.)
Venlafaxine 8745.2 0 0.0 (0.0,0.3)
Duloxetine 10,300.9 1 0.1 (0.0, 0.5) 0.5 (0.0, 9.1)
SSRI 9753.0 2 0.2 (0.0, 0.7)
Duloxetine 8035.8 1 0.1 (0.0, 0.7) undef. (0.0, inf.)
Untreated 5932.0 0 0.0 (0.0, 0.5)
ORD Optum Research Database, IR incidence rate, representing number of events per 1000 person-years, CI confidence interval, IRR incidence rate ratio, NA not
available, undef.undefined, inf. infinity
aOne case of other clinically significant hepatic injury in the duloxetine cohort was initially confirmed by independent adjudicators as a confirmed case without
alternate etiology. However, following a post hoc review by the adjudicators, this case was classified as a hepatic injury with alternate etiologies. Because we
conducted this post hoc review outside of the protocol, the case remains in these data as a confirmed case without alternate etiology
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propensity score-matched venlafaxine users, but not
relative to SSRIs. Our study – which expanded accrual
to include data from the first 6 years following the
launch of duloxetine and was restricted to patients with-
out baseline hepatic disorders as identified using the
health care claims – provides additional information
suggestive of an increased incidence of hepatic events of
lesser severity among duloxetine initiators relative to
clinically relevant comparators. The IRs observed in our
study are lower (albeit within the confidence limits)
Table 6 IRs, IRRs, and 95 % confidence intervals of hepatic events irrespective of determination of alternate etiology, follow-up
through 15 days following treatment discontinuation, matched duloxetine and comparator cohorts, ORD, 01 August 2004 to 31
December 2010
Outcome Cohort Person-Years No. Cases IR 95 % CI IRR 95 % CI
Hepatic-related death Duloxetine 7633.5 0 0.0 (0.0, 0.4) NA NA
Venlafaxine 8838.7 0 0.0 (0.0, 0.3)
Duloxetine 10,411.9 0 0.0 (0.0, 0.3) NA NA
SSRI 9835.6 0 0.0 (0.0, 0.3)
Duloxetine 8116.7 0 0.0 (0.0, 0.4) NA NA
Untreated 5966.1 0 0.0 (0.0, 0.5)
Hepatic failure Duloxetine 7631.7 0 0.0 (0.0, 0.4) NA NA
Venlafaxine 8836.6 0 0.0 (0.0, 0.3)
Duloxetine 10,410.6 0 0.0 (0.0, 0.3) NA NA
SSRI 9833.9 0 0.0 (0.0, 0.3)
Duloxetine 8116.2 0 0.0 (0.0, 0.4) NA NA
Untreated 5965.8 0 0.0 (0.0, 0.5)
Other clinically significant hepatic injury Duloxetine 7548.5 11 1.5 (0.7, 2.6) 3.2 (0.9, 13.7)
Venlafaxine 8745.2 4 0.5 (0.1, 1.2)
Duloxetine 10,300.9 14 1.4 (0.7, 2.3) 1.3 (0.5, 3.3)
SSRI 9753.2 10 1.0 (0.5,1.9)
Duloxetine 8035.8 11 1.4 (0.7, 2.4) 1.0 (0.4, 2.9)
Untreated 5931.9 8 1.3 (0.6, 2.7)
Hepatic-related death and liver failure combined Duloxetine 7631.7 0 0.0 (0.0,0.4) NA NA
Venlafaxine 8836.6 0 0.0 (0.0, 0.3)
Duloxetine 10,410.6 0 0.0 (0.0, 0.3) NA NA
SSRI 9833.8 0 0.0 (0.0, 0.3)
Duloxetine 8116.2 0 0.0 (0.0, 0.4)NA NA
Untreated 5965.6 0 0.0 (0.0, 0.5)
All clinically significant hepatic categories combined Duloxetine 7548.5 11 1.5 (0.7, 2.6) 3.2 (0.9, 13.7)
Venlafaxine 8745.2 4 0.5 (0.1, 1.2)
Duloxetine 10,300.9 14 1.4 (0.7, 2.3) 1.3 (0.5, 3.3)
SSRI 9753.2 10 1.0 (0.5, 1.9)
Duloxetine 8035.8 11 1.4 (0.7, 2.4) 1.0 (0.4, 2.9)
Untreated 5931.9 8 1.3 (0.6, 2.7)
Non-serious hepatic enzyme elevation Duloxetine 7548.5 1 0.1 (0.0, 0.7) undef. (0.0,inf.)
Venlafaxine 8745.2 0 0.0 (0.0, 0.3)
Duloxetine 10,300.9 1 0.1 (0.0, 0.5) 0.5 (0.0,9.1)
SSRI 9753.0 2 0.2 (0.0, 0.7)
Duloxetine 8035.8 1 0.1 (0.0, 0.7) 0.7 (0.0,57.9)
Untreated 5932.0 1 0.2 (0.0, 0.9)
ORD Optum Research Database, IR incidence rate, representing number of events per 1000 person-years, CI confidence interval, IRR: rate ratio, NA not available,
undef. undefined, inf. infinity
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compared with estimated IRs reported in a study by Shin
et al., [20] which identified and evaluated the incidence
and outcomes of drug-associated liver injury using elec-
tronic medical record data and that similarly restricted
the study population to patients without evidence of pre-
existing liver disease or other comorbidity to minimize
capture of non-drug-related liver injury.
This study has several limitations and considerations.
The statistical power of this study to evaluate relative
risks was limited due to the rarity of these outcomes.
We observed no cases of hepatic-related death or liver
failure in the duloxetine or the three comparator
cohorts, and this study does not demonstrate an associ-
ation with duloxetine use. Previously published estimates
suggest liver injury potentially associated with duloxetine
is infrequent [4, 20]; our study (comprising 7500 to
10,000 person-years of duloxetine exposure) had limited
power to identify clinically significant injury between
study groups. While assessments of whether risk for liver
injury is modified by the presence of underlying liver
disease is an important clinical question, the primary
interest of this study was to evaluate potential for in-
creased risk in a more homogeneous population of pa-
tients in terms of baseline risk, as follow on to that
reported by Xue et al.[8]. To minimize the capture of
non-drug-related liver injury and provide a specific focus
on clinically significant potential drug-related liver in-
jury, this study was restricted to subjects without pre-
existing liver conditions. The objective of this study was
to estimate the absolute and relative incidence of clinic-
ally significant hepatic events among patients with de-
pression and without pre-existing liver disease who
initiated duloxetine relative to each of the following pro-
pensity score-matched comparison cohorts: patients
with depression who initiated venlafaxine, patients with
depression who initiated SSRIs, and patients with a diag-
nosis of depression who did not receive treatment. In
addition, we followed patients for the occurrence of liver
injury during the time patients were actively on treat-
ment (plus 15 days after treatment cessation), further
limiting statistical power. An assessment of potential
chronic liver injury could also improve power, but falls
outside the scope of our study. As an observational
study, patients who received duloxetine may differ from
those who received a comparator drug or those who did
not receive any pharmacological treatment for depres-
sion. If these differences are associated with hepatic in-
jury, then the comparison of the duloxetine initiators to
comparators may be biased. Duloxetine initiators and
their comparators were not matched directly on specific
baseline characteristics. Instead, this study used propen-
sity score techniques to match a comparator group to
the exposed cohort and address potential confounding
by numerous covariates that are integrated into this
single variable; comparison of the duloxetine initiators
to the comparator cohorts suggested the cohorts were
well-balanced for the claims-based covariates included
in the propensity score model. The challenge of identify-
ing potential cases of drug-induced liver injury on the
basis of ICD-9 codes in terms of sensitivity and specifi-
city has been noted previously [21, 22]. In our study, we
sought to procure and review medical records for all po-
tential cases to verify the occurrence of a drug-induced
liver injury event, and the low yield of confirmed cases
from our chart validation is consistent with expectation.
Because we were not able to obtain all of the medical re-
cords sought (74 % obtained), some study events could
not be confirmed. This led to reduced statistical power
and reduced estimates of the absolute incidence rates.
However, the proportion of medical records obtained
was similar across the study cohorts, with the expect-
ation that the comparisons were not differentially af-
fected and therefore should be unbiased.
While balanced on claims-based covariates, informa-
tion obtained from the medical records in the baseline
validation sample suggests that duloxetine initiators may
have differed from the comparator cohorts on certain
characteristics that may not be adequately captured
using the health care claims (e.g., smoking, pain-related
syndromes, alcohol use/abuse). Medical record docu-
mentation of important potential confounders may itself
be incomplete or differentially captured (e.g., alcohol use
or abuse). Residual confounding by covariates not avail-
able from medical records is also possible. However, the
balancing of measured characteristics achieved by pro-
pensity score limits the extent of the confounding that is
possible. The US product label of duloxetine includes
hepatotoxicity in the “Warnings and Precautions” sec-
tion and warns against prescribing this drug to patients
with substantial alcohol use or evidence of chronic liver
disease [23]. If heightened awareness of the risk for hep-
atotoxicity led clinicians to conduct more comprehen-
sive assessments when deciding to prescribe duloxetine
or as a part of monitoring therapy, the resulting surveil-
lance bias may have led to differential rates of diagnosis
of hepatic injury. This study was restricted to a commer-
cially insured population of patients without pre-existing
hepatic conditions, and results may not be generalizable
to the general patient populations who ultimately may
use the drug.
This study made use of propensity score methods to
account for potential confounding and further mitigated
potential confounding from the presence of pre-existing
hepatic disease through restriction of the study popula-
tion to patients without baseline hepatic disorders (on
the basis of the health care claims). In addition, this
study focused on clinically significant potentially drug-
associated liver injury events, validated by medical
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record review, occurring while exposed to a drug of
interest or up to 15 days after last drug availability to
evaluate the risk of idiosyncratic drug-induced liver in-
jury at the typical time of its occurrence. By supplement-
ing covariate ascertainment through medical record
review, this study was able to assess the potential role of
unmeasured confounding as a plausible explanation for
the observed associations. Study outcomes were adjudi-
cated through medical record review to ensure that the
observed cases of hepatic injury actually occurred and
were not simply rule-out diagnoses in an administrative
database. The broad initial screen for potential cases
coupled with clinical adjudication addresses both the
sensitivity and the specificity of case identification.
Even with this rigorous assessment of study outcomes,
one case of other clinically significant hepatic injury in
the duloxetine cohort was initially confirmed by the in-
dependent adjudicators as a confirmed case without al-
ternate etiology. However, following a post hoc review by
the adjudicators, this case was classified as a hepatic in-
jury with alternate etiologies. This subsequent finding
suggests that there is some variability in determination
of alternate etiology by the same reviewer over time, at
least for this case. The additional medical record review
was prompted by the observation that this case had
claims consistent with alternate etiologies. The re-review
was not applied systematically to all potential cases and,
therefore, not all cases had the same opportunity to re-
ceive an alternate designation.
We chose not to conduct a re-review of all cases, and
the analyses presented were based on the results of the
initial case adjudication. There could be no guarantee
that a second review would be more accurate than the
initial review. Indeed, a small risk of misclassification is
inherent when humans are involved in the adjudication
process. This misclassification is, in expectation, non-
differential with respect to exposure because we blinded
the reviewed medical records with respect to exposure
status. Given the limited statistical power of the study,
despite any modifications to case classification or ana-
lyses, the study data would remain imprecise.
Conclusions
This study observed no cases of hepatic-related death or
liver failure in initiators of duloxetine or the 3 compara-
tor cohorts, and this study does not demonstrate an
association with duloxetine use. Applying a rigorous
methodology that addresses confounding and outcome
certainty, our findings while statistically not significant,
may suggest an elevated IR of other clinically significant
hepatic injury among duloxetine initiators compared to
initiators of venlafaxine and possibly initiators of SSRIs,
but not relative to pharmacologically untreated patients.
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